[1]Stolerman ES, Florez JC. Genomics of type 2 diabetes mellitus: implications for the clinician[J]. Nat Rev Endocrinol, 2009, 5(8): 429-436.
[2]中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013版)[J]. 中华糖尿病杂志, 2014, 6(7): 447-498.
[3]Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient centered approach update to a position statement of the American diabetes association and the European association for the study of diabetes[J]. Diabetes Care, 2015, 38(1): 140-149.
[4]Israili ZH. Advances in the treatment of type 2 diabetes mellitus[J]. Am J Ther, 2011, 18(2): 117-152.
[5]吴小秋, 刘志龙, 张凰, 等. 早期胰岛素强化治疗联合生脉注射液对2型糖尿病血管炎症因子的影响[J]. 长春中医药大学学报, 2014, 30(2): 295-297.
[6]王思佶, 彭永富, 夏培元. 重庆地区20家医院2006~2008年抗糖尿病药利用分析[J]. 中国药房, 2010, 21(42): 3958-3960.
[7]赵玮. 北京地区40余家医院2007~2009年口服降糖药利用分析[J]. 中国药房, 2010, 21(42): 3951-3953.
[8]母义明, 纪立农, 宁光, 等. 二甲双胍临床应用专家共识[J]. 中国糖尿病杂志, 2014, 8(22): 673-681.
[9]Ito H, Ishida H, Takeuchi Y, et al. Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus[J]. Nutr Metab, 2010, 7: 83.
[10]Donnelly LA, Doney AS, Hattersley AT, et al. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes[J]. Diabet Med, 2006, 23(2): 128-133. |